Multimodal analysis of the effects of dexamethasone on high-altitude cerebral oedema : protocol for a pilot study by Fisher, O. et al.
STUDY PROTOCOL Open Access
Multimodal analysis of the effects of
dexamethasone on high-altitude cerebral
oedema: protocol for a pilot study
O. Fisher1,2* , R. A. Benson1,3, S. Wayte1, P. K. Kimani2, C. Hutchinson1,2 and C. H. E. Imray1,2
Abstract
Background: Acute mountain sickness (AMS) is a cluster of symptoms that commonly occur in those ascending to
high altitudes. Symptoms can include headaches, nausea, insomnia and fatigue. Exposure to high altitude can also
lead to high-altitude cerebral oedema (HACE), which is a potential cause of death whilst mountaineering. Generally,
AMS precedes the development of HACE. Historical studies have demonstrated the effectiveness of regular
dexamethasone administration in reducing the symptoms of AMS. However, the mechanism by which
dexamethasone works to reduce symptoms AMS remains poorly understood. Further studies, simulating altitude
using hypoxic tents, have characterised the effect of prolonged exposure to normobaric hypoxia on cerebral
oedema and blood flow using MRI. This randomised trial assesses the effect of dexamethasone on hypoxia-induced
cerebral oedema in healthy adult volunteers.
Methods/design: D4H is a double-blind placebo-controlled randomised trial assessing the effect of
dexamethasone on hypoxia-induced cerebral oedema. In total, 20 volunteers were randomised in pairs to receive
either 8.25 mg dexamethasone or normal saline placebo intravenously after 8 h of hypoxia with an FiO2 of 12%.
Serial MRI images of the brain and spinal cord were obtained at hours 0, 7, 11, 22 and 26 of the study along with
serum and urinary markers to correlate with the severity of cerebral oedema and the effect of the intervention.
Discussion: MRI has been used to identify changes in cerebral vasculature in the development of AMS and HACE.
Dexamethasone is effective at reducing the symptoms of AMS; however, the mechanism of this effect is unknown.
If this study demonstrates a clear objective benefit of dexamethasone in this setting, future studies may be able to
demonstrate that dexamethasone is an effective therapy for oedema associated with brain and spinal cord
ischaemia beyond AMS.
Trial registration: Clinicaltrials.gov, NCT03341676. Registered on 14 November 2017.
Keywords: Altitude, hypoxia, cerebral oedema, steroid, acute mountain sickness, MRI
Background
Acute mountain sickness (AMS) is a cluster of symp-
toms that commonly occur in those ascending to high
altitudes (>1500 m), including headaches, nausea, insom-
nia and fatigue [1]. Exposure to high altitude can also
lead to the more dangerous high-altitude cerebral
oedema (HACE), which is a potential cause of death
whilst mountaineering. Whether HACE and AMS
belong to the same pathophysiological spectrum is a
matter of debate, although generally AMS precedes the
development of HACE.
Magnetic resonance imaging (MRI) studies have dem-
onstrated the impact of prolonged periods at altitudes of
up to 4350m on cerebral white matter volume and cere-
bral blood flow. Hypoxia is associated with a compensa-
tory increase in cerebral blood flow and a subsequent
increase in brain volume, which can be demonstrated
through MRI [2]. The increasing use of hypoxic tents to
induce AMS has allowed interval imaging and a clearer
demonstration of both the timing and patterns of
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oedema development in the brain [3]. MRI is useful for
monitoring the brain during these periods, as directly
measuring the intracranial pressure is difficult to do or
justify in healthy volunteers whereas the intracranial
pressure can be inferred indirectly using the change in
the volume of different intracranial tissues [3]. Kallen-
berg et al. used diffusion-weighted imaging (DWI) to
demonstrate that AMS sufferers have a decreased appar-
ent diffusion coefficient (ADC), a measure of how freely
water can move between tissues [4–6]. The drop in
ADC suggests cytotoxic oedema is an important compo-
nent of AMS. This mechanism has many similarities
with the accepted pathophysiology of cytotoxic oedema
during cerebral ischaemia [7]. Compared to healthy tis-
sue, the ischaemic spinal cord, like the brain, also shows
a drop in ADC on DWI accompanied by hyperintensity
on T2-weighted imaging [8–11]. Zhang [11] used canine
models to demonstrate that changes in DWI and T2-
weighted imaging are visible within an hour of inducing
spinal cord ischaemia.
Double-blind studies simulating altitude have already
demonstrated the effectiveness of regular dexametha-
sone administration in reducing the symptoms of AMS.
Johnson et al. compared 6 hourly dexamethasone (4 mg
dose) to a placebo in 16 men exposed to a simulated
altitude of 4570 m using a hypobaric chamber [12]. A
meta-analysis by Tang et al. [13] of using oral dexa-
methasone to treat AMS calculated an odds ratio of 6.03
(95% confidence interval, 2.23–21.00, p ≥ 0.05) com-
pared to a placebo.
Multiple peripheral serum biomarkers of cerebral or
blood–brain barrier dysfunction are currently under in-
vestigation; however, none have previously been applied
to AMS and HACE. Glial fibrillary acidic protein
(GFAP) is an intermediate filament protein that is up-
regulated in astrocytes following neuronal injury. There
is good experimental correlation with neurological dam-
age after a stroke or traumatic brain injury. Purine nu-
cleosides (adenosine, inosine and hypoxanthine) have
also been found to be sensitive early markers of ischae-
mic brain events [14, 15]. α-1 acid glycoprotein has re-
cently been shown to act as a more sensitive marker of
proteinuria than the more widely utilised urinary pro-
tein, albumin [16]. In animal models, the presence of
proteinuria has been demonstrated to precede cerebral
oedema and has been demonstrated to modulate the
permeability of the blood–brain barrier [17, 18], as well
as correlating with exposure to hypoxia [19].
Despite evidence for its efficacy, the mechanism be-
hind the effect of dexamethasone remains poorly under-
stood. Therefore, it has not been validated as a true
therapeutic solution to AMS or HACE. This study aims
to provide evidence of the mechanisms of action and
therapeutic potential of dexamethasone for the
treatment of symptomatic AMS and other causes of
cerebral and spinal cord oedema and to investigate and
correlate changes in peripheral serum biomarkers in re-
sponse to hypoxia with radiological findings.
Methods/design
Study design
D4H is a phase-I double-blind placebo-controlled rando-
mised control trial assessing the effect of dexamethasone
on hypoxia-induced cerebral oedema in healthy adult
volunteers.
Hypothesis
A single dose of intravenous dexamethasone given after
8 hours in normobaric hypoxia at 12% inspired oxygen
concentration (FiO2) reduces the incidence or severity
of the symptoms of AMS, as determined by MRI
changes due to cerebral oedema.
Primary objective
To identify any measurable differences in:
1. Lake Louise scores
2. prespecified MRI parameters
following prolonged normobaric hypoxia after adminis-
tration of a single dose of intravenous dexamethasone
compared to a placebo.
Secondary objectives
1. To measure the integrity of the blood–brain barrier
and astrocyte dysfunction using proxy
measurements (serum purine levels and GFAP) and
correlate these with primary outcome measures.
2. To correlate proteinuria with the primary outcome
measures.
Sample size
Estimates from our previous observational study of MRI
differences at normobaric hypoxia were used to deter-
mine the power [3]. It was assumed that dexamethasone
will reverse outcome measures to their baseline values.
Powers for pairwise comparisons at 22 h for three differ-
ent significance levels (0.05, 0.10 and 0.20) and for three
outcome measures that showed change at 22 h from
baseline in the observational work were calculated by as-
suming that the data are normally distributed, (Table 1).
Since most of the other outcomes showed smaller differ-
ences, it was decided to test hypotheses at 20% signifi-
cance and make this study a pilot study.
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Inclusion and exclusion criteria
Subjects between the ages of 18 and 35 with a body mass
index <30 kg/m2 who have not been to an altitude
greater than 1500 m within 12 weeks were invited to par-
ticipate. They provided written informed consent, which
was obtained by a medically qualified doctor, as dele-
gated by the chief investigator.
Patients with any systemic illness, currently pregnant
or breastfeeding, or with recorded contra-indications to
taking dexamethasone or having an MRI were excluded.
Patients with a medical history of hypertension, un-
treated respiratory disease, glaucoma, epilepsy, peptic
ulcer, recent surgery or known intra-cranial pathology
were also ineligible.
Randomisation
Once eligibility had been confirmed, participants were
allocated to the treatment or placebo group via block
randomisation. The participants were randomised in
sex-matched pairs and the randomisation sequence allo-
cated participants attending on the same day to the same
study arm to prevent unintentional unblinding of partici-
pants or investigators during the visit. The randomisa-
tion list was generated by computer by a statistician.
Except in the case of an adverse event (AE) requiring
unblinding, only the statistician who generated the list
and the pharmacist are not blinded to study allocation.
They are not members of the trial management group.
Intervention
Subjects in the placebo group received a single dose of
0.9% sodium chloride (8.2 mL) as the placebo, which was
administered as a bolus injection intravenously over 5
min at 8 h post-baseline (0 h). Subjects in the interven-
tion group received a single dose of dexamethasone 8.25
mg (2.5 mL) made up to 8.2 mL with 0.9% sodium chlor-
ide, which also was administered as a bolus injection
intravenously over 5 min at 8 h post-baseline (0 h).
Schedule of events
Each subject visited the study site twice, the first time
for a screening and consent visit and the second time for
a period of 26 h for the study itself. A diagrammatic rep-
resentation of patient flow through the trial is shown in
Fig. 1. A full schedule of investigations, interventions
and procedures to be performed at each study visit is
shown in Table 2.
Visit 1 – Screening
Volunteers were invited to attend University Hospitals
Coventry and Warwickshire NHS Trust (UHCW) for
screening and enrolment. Screening included baseline
observations, a comprehensive health and MRI eligibility
questionnaire, a pregnancy test if applicable and baseline
blood tests. Consent included entering their personal in-
formation into the Health Research Authority’s Over-
Volunteering Prevention System (TOPS). Once a poten-
tial participant had provided permission, the researcher
sent a letter and copy of the participant information
sheet to the participant’s general practitioner to inform
them of their participation in the study.
Visit 2 – Intervention
Confirmation of eligibility and safety checks The
interventional study visit took place over 26 h in the
MRI suite at UHCW. Any participants failing to meet
the eligibility criteria on the day of intervention were
withdrawn from the trial. Information on the last urine
void time, a Lake Louise Acute Mountain Sickness self-
assessment score, venous blood samples and baseline
observations were recorded. The first MRI scan was then
performed and used for baseline values.
Hypoxication Following the assessment at hour 0, par-
ticipants experienced 24 h of normobaric hypoxia at spe-
cific oxygen concentrations using a hypoxication tent
(Everest Summit Hypoxic Generator, Hypoxic Systems,
New York). The hypoxication tent is a self-contained
structure measuring approximately 2 m (w) × 2.5 m (l) ×
1.8 m (h), in which the oxygen levels are tightly con-
trolled. Participants may leave the tent during the inter-
vention, during which time they will wear a mask
attached to a portable hypoxicator to make sure the in-
spired oxygen concentrations are controlled. Participants
will continue with normal activities while in the tent,
such as eating and sleeping. The time from which the
participant begins to inspire hypoxicated air (FiO2 12%)
marks the start of hour 1. Subsequent observations were
taken on the hour, plus or minus 30min to allow for
Table 1 Power for different outcomes and significance levels
Outcome Estimates from Sagoo et al. [3] Power
Difference Standard deviation α = 0.05 α = 0.10 α = 0.20
Blood oxygen content, ml O2/dL blood 2.05 1.33 97 98 99
Whole-brain ADC × 10–4/mm3 0.5 0.45 78 86 93
Corpus callosum (genu) ADC × 10–4/mm3 (mean of right and left) 1.35 1.65 52 64 77
ADC apparent diffusion coefficient
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any unanticipated delays during the study visit. At hour
25, the participant returned to breathing oxygen at nor-
mal atmospheric pressure (FiO2 21%). The hypoxication
schedule is shown in Table 3.
Three hypoxic generators were used to control the en-
vironment. Carbon dioxide build-up was controlled with
an air pump (Bair Hugger™, 3M, Berkshire, UK). Air
from the tent was pumped through two soda lime scrub-
bers (Spherasorb™, medical grade soda lime from
Intersurgical Ltd, UK, in canisters by Draeger Medical
UK Ltd). These were replaced after 12 h.
Outcome measures
MRI Sequences performed in the brain have previously
been found to produce significant results [3]. This im-
aging included assessment of the diameter and flow rate
within the middle cerebral artery using 3D time of flight
Fig. 1 Participant flow diagram. IMP investigational medicinal product
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and 2D phase contrast MR angiography, respectively. In
the present study, whole-brain DWI was used to pro-
duce ADC maps to quantify brain oedema. A T1-
weighted total brain volume sequence was used to calcu-
late changes in brain parenchymal and cerebrospinal
fluid volumes as a result of cerebral oedema. T2*-based
susceptibility-weighted imaging identified changes in
the deep cerebral venous anatomy and found evidence
of venous compression secondary to cerebral oedema.
In addition, sequences were acquired to assess the
cervical spinal cord volume and the total cord length.
The flow rate in the internal carotid artery was mea-
sured using 2D phase-contrast MR angiography. The
acquisition parameters used for all the MR sequences
are given in Table 4.
Blood sampling Venous blood was taken immediately
prior to each MRI scan and haematology and biochemis-
try markers were measured, including full blood count,
renal function, erythrocyte sedimentation rate and levels
of C-reactive protein. Serum samples were stored imme-
diately at −80°C for a later GFAP analysis. Finger-prick
capillary blood samples for purine assessment were also
obtained at these time points.
Urine samples Urine samples were collected and proc-
essed for every urine void during the intervention. The
samples collected will be a spun down via centrifuge and
were stored in a monitored freezer set to maintain tem-
peratures of -70° to -85 °C. Samples were frozen within 1
hour of collection.
Clinical assessments Vital signs were monitored every
2 h between hours 0–11 and hours 22–26. After the
MRI scan at hour 0, the scans were repeated at hours 7,
11, 22 and 26. Participants were asked to complete the
Lake Louise Acute Mountain Sickness Questionnaire at
hours 2, 4, 6, 8, 11, 22 and 26. The Lake Louise score is
a validated tool for diagnosing and scoring the severity
of AMS [20]. Five questions (headache, gastrointestinal
upset, fatigue, dizziness and sleep disturbance) were
graded 0 (none) to 3 (severe) by participants. A total
score of 3 is considered diagnostic of AMS. A score of
6–9 is considered moderate AMS and a score of 10 or
above is considered severe AMS. In this study, the Lake
Louise score was used to monitor participants for the
development of AMS. If a participant had a score of 6 or
above or an increase in total score of 2 or greater from
the previous score, then consideration was made about
withdrawing them from the study. Inspired O2 and CO2
were measured every 15 min from hours 1 to 9 and
thereafter every 30 min from hours 10 to 24.
Preparation, storage and administration of the
investigational medicinal product The investigational
medicinal product (IMP) was prepared for administration,
labelled and stored in the trust’s aseptic laboratory for a
maximum of 24 h prior to the study visit. Dexamethasone
Table 3 Schedule of participant hypoxication
Timeline Inspired oxygen concentration (FiO2)
Baseline Normal atmospheric O2 (21%)
Hours 1–12 12%
Hours 13–21 13.5%
Hours 22–24 12%
Hours 25–26 Normal atmospheric O2 (21%)
Table 4 Technical MRI sequence parameters
Sequence Purpose TR
(ms)
TE
(ms)
Flip
angle (°)
FoV
(mm)
Matrix Slice width/
slice gap (mm)
Acquisition
time
Comment
3D time of flight Asses diameter MCA 27 5.7 20 210 × 210 384 × 256 1.2/0.0 3 min 10 s
2D phase contrast Assess flow in MCA 11 5.2 30 160 × 160 256 × 224 5.0 4 min 7 s 1 slice, 25 phases
venc = 120 cm s− 1
Diffusion-weighted
imaging
Produce ADC maps to
quantify brain oedema
13,
729
86.2 – 240 × 240 256 × 256 4.0/1.0 5 min
57 s
b = 0, 800 and 1000
s.mm−2
T1 3D FSPGR Assess brain and CSF
volume
8.5 3.3 12 240 × 180 256 × 256 1.8/0.0 5 min TI = 400ms Reconstructed
to 0.9 mm slice width
SWI Changes in venous
volume
50.9 23.7 10 240 × 240 320 × 288 2.0/0.0 6 min
41 s
Reconstructed to 1 mm
slice width
T2 3D FSE (cube) Volume of the
cervical spinal cord
1250 92.2 – 180 × 180 288 × 288 2.0/0.0 3 min 35 s Reconstructed to 1 mm
slice width
Sagittal T2 Assess total cord
length
3406 106.3 – 440 × 440 384 × 288 4.0/0.0 1 min 56 s Images combined to
produce a single image
2D phase contrast Assess flow in the
internal carotid arteries
10.5 4.9 30 160 × 160 256 × 224 5.0 4 min 21 s 1 slice, 25 phases
venc = 120 cm s− 1
ADC apparent diffusion coefficient, CSF cerebrospinal fluid, FoV field of view, FSE fast spin echo, FSPGR fast spoiled gradient echo, MCA middle cerebral artery,
SWI susceptibility-weighted imaging, TE echo time, TI inversion time, TR repetition time
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must not be stored above 25 °C and cannot be refrigerated
or frozen. The study medication was stored in a
temperature-controlled box. A temperature log ensured it
remained within the acceptable temperature range until
use. Any medication found to have breached the specified
temperature range was discarded. On the intervention
day, a member of the study team collected the prepared
IMP for administration to the participants. Participants
were randomised to receive a single dose of either the pla-
cebo or dexamethasone at hour 8 of the intervention visit.
A medical doctor, as delegated by the chief investigator,
prescribed and administered the study medication.
Statistical analysis
Summary of baseline data and flow of patients Data
exploration will include comparing the baseline charac-
teristics of the volunteers in the placebo and dexametha-
sone groups. For continuous characteristics such as age,
we will report the mean, median, range, interquartile
range and standard deviation. Differences between the
two groups will be compared using the Mann–Whitney
U test. For categorical data such as gender, we will re-
port the number and percentage of cases in each cat-
egory. Fisher’s exact test will be used to compare the
two groups.
Statistical analysis plan As in Sagoo et al. [3], it
thought plausible to assume that the outcomes would be
normally distributed. We will assess this assumption
using the residuals from models that assume the data
are normally distributed. If the residuals are not nor-
mally distributed, we will transform the raw data and re-
peat the normality assumption check.
Ultimately the primary aim of the study is to compare
outcomes between placebo and dexamethasone groups
at 22 h. The comparisons could be made by performing
t-tests using data collected at 22 h. This is, however, in-
efficient and so potentially to increase power, we will in-
clude outcome measures for all time points. To account
for the correlation among measurements taken from the
same volunteer at multiple time points, we will analyse
data by fitting linear mixed models. Separate linear
mixed models will be fitted for different outcomes. Each
linear mixed model will include a fixed term(s) for the
time at which a measurement was taken, a fixed term
for the treatment group of the volunteer and an inter-
action term for time and treatment group. The inter-
action term enables us to make inference for the mean
difference between the placebo and dexamethasone
groups at different time points. If there is an imbalance
of a baseline characteristic, a fixed term for the charac-
teristic will be included in the model. Outcome meas-
urement profiles over time will be assessed first. If the
relationship is approximately linear, a linear term for
time will be fitted. If not, time will be taken as a categor-
ical variable.
For data taken at 22 h, we will report the estimated mean
differences, the 95% confidence interval for the mean differ-
ences of the primary outcome measures and p values to test
the hypothesis that the mean difference is zero. As men-
tioned previously, because this is a pilot study, the hypoth-
esis will be tested at a 20% significance level. Also, for the
same reason, we will not adjust for multiple hypotheses
(corresponding to different outcome measures).
The above analysis plan will be used if it is plausible to
assume that the data are normally distributed. If a trans-
formation does not achieve normality, we will use non-
parametric methods such as the Mann–Whitney U test.
Participant withdrawal criteria
A participant would be withdrawn from the study during
the interventional visit in the following circumstances:
1. If the participant scores ‘severe’ for more than one
symptom on the Lake Louise Mountain Sickness
Score Questionnaire.
2. If it becomes medically necessary in the opinion of
the clinician overseeing the study visit.
3. The participant requests to be withdrawn at any
time.
In the event of withdrawal, the researcher will record
the reason for discontinuation and any AEs in the par-
ticipant’s notes.
Trial stopping rules
The trial will be stopped if:
1. A serious adverse reaction occurs that may be
related to the administration of the IMP to a
participant.
2. A severe non-serious adverse reaction occurs that
may be related to the IMP, regardless of the system
and organ class, to two participants.
In these circumstances, the trial steering committee,
data-monitoring committee, sponsor, research ethics
committee and the Medicines and Healthcare Products
Regulatory Agency will be notified within 24 h of receipt
of the initial report. Any participants actively involved in
the trial will be withdrawn and all trial activities will be
immediately discontinued.
Participant safety
A clinical member of the study staff was present in the
study area at all times during the interventional study
visit. Participants’ vital signs were monitored throughout
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the intervention period, except for hours 12–21, when it
was expected that the participant would be sleeping, un-
less the participant became unwell. A thorough risk as-
sessment of the study area was undertaken and approved.
Unblinding of investigators and participants is permitted
in the event of any AE, serious adverse event (SAE) or sus-
pected unexpected serious adverse reaction (SUSAR).
Unblinding will take place via codebreak envelopes stored
within the MRI suite and pharmacy at UHCW.
Trial oversight
Trial oversight is provided by the trial management
group. The trial steering committee will meet regularly
to review progress and the safety of the study. There is
also an independent data management group. The study
sponsor, UHCW, is a National Institute for Health Re-
search facility. The study was reviewed after the first two
participants to ensure the safety and quality measures
were met. After 20 patients had completed the protocol,
a preliminary analysis was performed, and if sufficient
differences had been seen, the study would have been
closed to recruitment. If not, recruitment will continue
to 30 patients. All potential AEs, as defined by good clin-
ical practice (AEs, SAEs or SUSARs), were compiled by
the trial manager and statistician and reviewed by the
sponsor. All Grade IV AEs, all SAEs and all SUSARs
were reported to the trial management group within 24
h. Participant information will be held securely at the
trial sponsor site until study closeout, when they will be
transferred to a third-party storage facility with appro-
priate security, and fire and flood provisions.
Discussion
Previous studies have used MRI to identify changes in
cerebral vasculature in the development of AMS and
HACE. Since dexamethasone is therapeutic in this set-
ting, the next stage of research is to demonstrate that
dexamethasone administration has a direct effect on
cerebral vasculature during a prolonged period of nor-
mobaric hypoxia to provide evidence of the mechanisms
behind the development of AMS. If this study demon-
strates a clear benefit of dexamethasone in this setting,
the aim is to conduct further studies to include patients
suffering from similar cerebral and spinal cord oedema
due to other causes of cerebral hypoxia and spinal cord
ischaemia. Ultimately, we would like to discover whether
dexamethasone is an effective therapy for oedema asso-
ciated with brain and spinal cord ischaemia.
Trial status
This is protocol version 2.0, dated 25 July 2018. The
scheduled start of recruitment was 2 February 2019. The
anticipated end of recruitment was March 2020.
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